Auris Health

Encision Inc. signed a three-year supply agreement with Auris Health, Inc., part of Johnson & Johnson Medical Devices Companies, for AEM Technology-enabled products. Auris will buy certain products exclusively from Encision, with upfront and milestone payments.

Johnson & Johnson, through its subsidiary Ethicon, Inc., has entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies for lung cancer, for approximately $3.4 billion in cash, with additional contingent payments of up to $2.35 billion.

Johnson & Johnson subsidiary Ethicon closed a $3.4bn acquisition of surgical robotics developer Auris Health. The deal includes up to $2.35bn in additional contingent payments.

Johnson & Johnson announced that its subsidiary Ethicon has agreed to acquire Auris Health for approximately $3.4 billion in cash, with additional contingent payments up to $2.35 billion. Auris Health develops robotic technologies for bronchoscopic procedures.